alexa Sterility Assurance of Parenteral Products Major Deficiency for Recall | OMICS International
ISSN: 2329-6887
Journal of Pharmacovigilance
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Sterility Assurance of Parenteral Products Major Deficiency for Recall

Lakshmi Prasanna Kolluru*

Medefil Inc., Glendale Heights, IL 60139, USA

*Corresponding Author:
Lakshmi Prasanna Kolluru
Sr. Formulation Scientist
Medefil Inc., 250/405 Windy Point Drive
Glendale Heights, IL 60139, USA
Tel: +1-612-865-7725
E-mail: [email protected]

Received Date: March 13, 2017; Accepted Date: March 17, 2017; Published Date: March 24, 2017

Citation: Kolluru LP (2017) Sterility Assurance of Parenteral Products–Major Deficiency for Recall. J Pharmacovigil 5:e168. doi: 10.4172/2329-6887.1000e168

Copyright: © 2017 Kolluru LP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacovigilance


Sterility is one of the most important Critical Quality Attribute (CQA) for all parenteral drug products as they are intended to circumvent body’s defense mechanisms and rapidly enter blood circulation. When the sterility of such products is compromised, it leads to microbial contamination of the drug product and/ or presence of particles leading to serious adverse events including death.

Lack of sterility assurance is a leading contributor to safety alerts and product recalls by Food and Drug Administration (FDA). Table 1 summarizes the safety alerts to parenteral products and drug manufacturers in 2016 [1]. Lack of sterility assurance can be product specific (probably caused by container closure integrity leakage) or manufacturing site specific (caused by poor facility and engineering or improper manufacturing practices) affecting all the drug products manufactured in the affected site. Such instances lead to major deficiencies during FDA facility inspections sometimes even leading to ceasing of all manufacturing operations until rectified [1-5].

Drug Product Manufacturer Reason for Recall
5% Dextrose Injection USP in PAB Container B. Braun Medical Inc. Leakage and/or Particulate Matter
Eye Wash/Eye Irrigating Solutions United Exchange Corp Microbial Contamination
Eye Saline Eye Wash Honeywell Microbial Contamination
Lyophilized HCG and Sermorelin Talon Compounding Pharmacy Lack of Sterility Assurance
Human and Animal Sterile Drug Products I.V Speciality Ltd Lack of Sterility Assurance
Sterile Drug Products Cantrell Drug Company Lack of Sterility Assurance
Sterile Drug Products Medaus Pharmacy Lack of Sterility Assurance
Sterile Drug Products Pharmakon Pharmaceuticals Lack of Sterility Assurance
Sterile Drug Products Tri-coast Pharmacy Lack of Sterility Assurance
Sterile Human and Animal Compounded Products Abbott Compounding Pharmacy Lack of Sterility Assurance
Sterile Compounded Products Well Care Compounding Pharmacy Lack of Sterility Assurance
Sterile Products Wells Pharmacy Network Lack of Sterility Assurance

Table 1: FDA safety alerts for drugs and biological products with compromised sterility in 2016.

Correction of sterility related deficiencies is usually time consuming and as it involves a team of facility engineers, manufacturing personnel, validation engineers and product development scientists to come together and fix the root cause of the problem. Hence, maintaining sterility of parenteral drug products throughout the product lifecycle and prevention of sterility related deficiencies is of utmost importance. Administrative bodies including FDA [6,7] and International Conference on Harmonization (ICH) [8,9] have developed set of guidance’s and reference procedures to be followed for successfully developing and testing a finished product with sterility assurance.

Various methods of sterilization including moist heat sterilization, dry heat sterilization, ethylene oxide sterilization or sterilization by aseptic filtration are available and a mode of sterilization is selected based on product specifications. As a general rule of thumb, terminal sterilization is the most preferred method of sterilization unless the container/closure system or drug product is not deemed to be suitable for terminal sterilization procedures [10,11].

Sterility of a finished product is assessed by monitoring microbial growth or turbidity as per USP <71> at product release and annually on stability throughout product shelf life [2]. Additionally, Bacterial Endotoxin Test (BET) is evaluated for all parenteral products as per USP <81> to monitor bio burden of the drug product [3]. Furthermore, Container Closure Integrity Testing (CCIT) is also evaluated on all drug products at release and on stability to ensure sterility of the drug products [4,5]. In addition to ensuring product sterility, care has to be taken to ensure appropriate environmental and engineering controls at the manufacturing site to develop a product with acceptable sterility assurance [6].

In conclusion, maintaining sterility of drug products intended for parenteral administration is of utmost importance and current good manufacturing practices to ensure sterility assurance has to be followed throughout product lifecycle.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 644
  • [From(publication date):
    April-2017 - Jan 24, 2018]
  • Breakdown by view type
  • HTML page views : 575
  • PDF downloads : 69

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version